Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listGDC-0879

GDC-0879

Synonym(s):1H-Inden-1-one, 2,3-dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-, oxime;2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-inden-1-one oxime;2-[4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol;5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime;

GDC-0879 Structural

What is GDC-0879?

The Uses of GDC-0879

GDC 0879 is a potent B-Raf inhibitor.

What are the applications of Application

GDC-0879 is a novel potent, selective Raf-B inhibitor

Definition

ChEBI: GDC-0879 is a member of the class of pyrazoles that is 1-(2-hydroxyethyl)pyrazole carrying additional 4-pyridyl and 1-(hydroxyimino)indan-5-yl substituents at positions 3 and 4 respectively. It has a role as a B-Raf inhibitor and an antineoplastic agent. It is a member of pyrazoles, a member of pyridines, a member of indanes, a ketoxime and a primary alcohol.

Biological Activity

gdc-0879 is synthsized as a potent and selective b-raf inhibitor. the raf/mitogen-activated protein kinase kinase (mek)/extracellular signal-regulated kinase signaling pathway is reported to be involved in cellular responses, which is relevant to tumorigenesis.

in vitro

gdc-0879 is a b-raf inhibitor against various in vitro and cell-based assays, such as a375 melanoma and colo205 colorectal carcinoma cell lines, both of which are v600e b-raf mutant. when screened against a panel of 140 kinases at its efficaciou dose, gdc-0879 showed expected activity only against c-raf [1].

in vivo

in mice treated by gdc-0879, both cell line-and patient-derived brafv600e tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant kras-expressing tumors. moreover, it was found that the responsiveness of brafv600e melanoma cells to gdc-0879 could be dramatically altered by pharmacologic and genetic modulation of phosphatidylinositol 3-kinase pathway activity [2].

storage

Store at -20°C

References

[1] wong h, belvin m, herter s, hoeflich kp, murray lj, wong l, choo ef. pharmacodynamics of 2-[4-[(1e)-1-(hydroxyimino)-2,3-dihydro-1h-inden-5-yl]-3-(pyridine-4-yl)-1h-pyrazol-1-yl]ethan-1-ol (gdc-0879), a potent and selective b-raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. j pharmacol exp ther. 2009 apr;329(1):360-7.
[2] hoeflich kp, herter s, tien j, wong l, berry l, chan j, o'brien c, modrusan z, seshagiri s, lackner m, stern h, choo e, murray l, friedman ls, belvin m. antitumor efficacy of the novel raf inhibitor gdc-0879 is predicted by brafv600e mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. cancer res. 2009 apr 1;69(7):3042-51.

Properties of GDC-0879

Density  1.37
storage temp.  Store at -20°C
solubility  insoluble in EtOH; insoluble in H2O; ≥16.7 mg/mL in DMSO
form  solid
color  Light yellow to light brown
Stability: Hygroscopic

Safety information for GDC-0879

Computed Descriptors for GDC-0879

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.